Johnson & Johnson Reports Third-Quarter 2013 Results - - BioPharm International

ADVERTISEMENT

Johnson & Johnson Reports Third-Quarter 2013 Results


Johnson & Johnson reported its 2013 third-quarter results, with sales of $17.6 billion up 3.1% as compared to the third quarter of 2012, the company announced in a press release. Operational results increased 4.7% and the negative impact of currency was 1.6%. International sales, up 4.2%, reflected operational growth of 7.1% and a negative currency impact of 2.9% and outpaced domestic US sales, which increased 1.7%.

For the third quarter of 2013, net earnings (attributable to Johnson & Johnson) were $3.0 billion and diluted earnings per share were $1.04. The company increased its earnings guidance for full-year 2013 to $5.44–5.49 per share, which excludes the impact of special items.

Worldwide pharmaceutical sales of $7.0 billion for the third quarter represented an increase of 9.9% over the previous year, with operational growth of 10.9% and a negative impact from currency of 1.0%. Domestic sales increased 7.9%. International sales increased 12.0%, which reflected an operational increase of 14.0% and a negative currency impact of 2.0%.

Primary contributors to operational sales growth were Invega Sustenna/Xeplion (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; Remicade (infliximab) and Simponi (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; Stelara (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; Velcade (bortezomib), a treatment for multiple myeloma; Prezista (darunavir), a treatment for HIV; and sales of new products.

Source: Johnson & Johnson

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines

Click here